ASH25 Preview – 10 abstracts to watch out for
In our first ASH preview we covered degraders, including BTK degraders, glue degraders, and degrader-ADCs (DACs).
It isn’t always bright and sunny in Orlando
This time around the topics and modalities vary in their nature, although they have what I call ‘interestingness’ in common.
They range in scope from antibodies, bispecifics, and CAR-T cells to T cell engagers and targeted therapies.
The intent here is more strategic than tactical where we explore some of the bigger picture competitive issues and look at where some of the new opportunities are emerging. In all fairness, not all of them will do well in our view so this is not a post for those looking for only rose tinted optimism…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
